RVMD icon

Revolution Medicines

40.38 USD
-0.29
0.71%
At close Apr 30, 4:00 PM EDT
After hours
40.38
+0.00
0.00%
1 day
-0.71%
5 days
7.94%
1 month
14.20%
3 months
-6.25%
6 months
-20.04%
Year to date
-8.23%
1 year
8.32%
5 years
29.13%
10 years
39.72%
 

About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Employees: 534

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

124% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 55

103% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 30

21% more funds holding in top 10

Funds holding in top 10: 19 [Q3] → 23 (+4) [Q4]

10% more capital invested

Capital invested by funds: $7.66B [Q3] → $8.44B (+$784M) [Q4]

10% more funds holding

Funds holding: 251 [Q3] → 276 (+25) [Q4]

4.75% more ownership

Funds ownership: 101.11% [Q3] → 105.86% (+4.75%) [Q4]

16% less call options, than puts

Call options by funds: $42.3M | Put options by funds: $50.2M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$59
46%
upside
Avg. target
$66
63%
upside
High target
$73
81%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
Robert Driscoll
9% 1-year accuracy
4 / 47 met price target
66%upside
$67
Outperform
Reiterated
28 Apr 2025
Needham
Ami Fadia
22% 1-year accuracy
35 / 160 met price target
46%upside
$59
Buy
Reiterated
8 Apr 2025
Stifel
Benjamin Burnett
38% 1-year accuracy
5 / 13 met price target
58%upside
$64
Buy
Maintained
1 Apr 2025
HC Wainwright & Co.
Robert Burns
27% 1-year accuracy
46 / 173 met price target
81%upside
$73
Buy
Maintained
3 Mar 2025

Financial journalist opinion

Based on 4 articles about RVMD published over the past 30 days

Neutral
GlobeNewsWire
6 hours ago
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
Positive
Benzinga
2 days ago
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?
Zoldonrasib showed a 61% objective response rate and 89% disease control rate in NSCLC patients at 1200 mg QD.
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?
Neutral
GlobeNewsWire
3 days ago
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Neutral
GlobeNewsWire
4 weeks ago
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Neutral
GlobeNewsWire
4 weeks ago
Revolution Medicines to Participate in April 2025 Investor Conferences
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in in two upcoming investor conferences.
Revolution Medicines to Participate in April 2025 Investor Conferences
Neutral
Seeking Alpha
2 months ago
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Conference Call Participants Eric Joseph - J.P. Morgan Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Ben Burnett - Stifel Laura Prendergast - Raymond James Jay Olson - Oppenheimer Joe Catanzaro - Piper Sandler Poorna Kannan - Needham & Company Alex Bouilloux - Barclays Bank Operator Good day, and thank you for standing by.
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 months ago
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
Neutral
GlobeNewsWire
2 months ago
Revolution Medicines to Participate in March 2025 Investor Conferences
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.
Revolution Medicines to Participate in March 2025 Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
Positive
Zacks Investment Research
2 months ago
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
Charts implemented using Lightweight Charts™